In this study, the genetic data (DNA) of brain tumours is described using molecular analysis techniques to enable more accurate diagnoses in paediatric oncology of the nervous system, as a complement to conventional pathological examination.
One of the reasons why brain tumours cannot yet be treated optimally and cured in all patients may be the not entirely clear classification of these cancers into clinically and biologically different groups. Other than the very well-established neuropathological and neuroradiological reference assessment, there is in most cases no systematic molecular description of these tumours.
MNP2.0 aims to pave the way for the widespread introduction of molecular diagnostics as the third pillar in the diagnosis of childhood brain cancers. Around 40 children and teenagers can take part in this research project in Switzerland every year.
The aim of the study is to describe the genetic information (DNA) in brain tumours with the aid of molecular analytical methods. This additional biological diagnostic procedure should reduce the rate of misdiagnosis and will permit subgroups to be identified that could be of great importance in taking therapy decisions.
The University clinic of Heidelberg and the Deutsche Krebsforschungszentrum in Germany are responsible for the international implementation of the study as sponsor. The Swiss Paediatric Oncology Group (SPOG) is responsible for performing the study in Switzerland (sponsor representative).
In short
-
The aim of the research project is to learn more about brain tumours in children and adolescents.
-
Molecular investigations are used to assign the tumours more accurately to various classes. The patients can then be treated more effectively thanks to the improved classification.
-
Study participants can benefit from this more accurate investigation of the tumour since the investigation results influence the treatment.
